<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Spinocerebellar <z:hpo ids='HP_0001251'>ataxia</z:hpo> type 3 (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">SCA3</z:e>) caused by polyglutamine-expanded ataxin-3 is the most prevalent subtype of spinocerebellar <z:hpo ids='HP_0001251'>ataxias</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>A compound, which decreases protein level of mutant ataxin-3 in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">SCA3</z:e> affected <z:chebi fb="7" ids="29425,29426,29441,29447">CNS</z:chebi> regions, should be a promising therapeutic agent for <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">SCA3</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain><z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">SCA3</z:e> and <z:e sem="disease" ids="C0020179" disease_type="Disease or Syndrome" abbrv="HD">Huntington's disease</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">HD</z:e>) belong to a family of polyglutamine <z:hpo ids='HP_0002180'>neurodegenerative diseases</z:hpo> </plain></SENT>
<SENT sid="3" pm="."><plain>Rho-kinase (ROCK) inhibitor Y27632 reduced brain level of polyglutamine-expanded huntingtin in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">HD</z:e> transgenic mouse </plain></SENT>
<SENT sid="4" pm="."><plain>Therefore, we tested the possibility that ROCK inhibitors, Y27632, H1152 and GSK429286, downregulate protein expression of polyglutamine-expanded ataxin-3-Q79 </plain></SENT>
<SENT sid="5" pm="."><plain>Y27632 or H1152 reduced protein level of HA-tagged ataxin-3-Q79 (ATX-3-Q79HA) expressed in HEK 293 cells </plain></SENT>
<SENT sid="6" pm="."><plain>Compared to Y27632, H1152 decreased ATX-3-Q79HA protein level with a significantly more potency and efficacy </plain></SENT>
<SENT sid="7" pm="."><plain>H1152 also reduced protein level of HA-tagged polyglutamine-expanded ataxin-7-Q52 (ATX-7-Q52HA), which causes spinocerebellar <z:hpo ids='HP_0001251'>ataxia</z:hpo> type 7 (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">SCA7</z:e>) </plain></SENT>
<SENT sid="8" pm="."><plain>H1152 decreased ATX-3-Q79HA or ATX-7-Q52HA protein level inÂ vitro by augmenting proteasome activity and promoting ATX-3-Q79HA or ATX-7-Q52HA degradation </plain></SENT>
<SENT sid="9" pm="."><plain>GSK429286, which is structurally different from H1152 but equally inhibits ROCK, failed to affect protein level of ATX-3-Q79HA or ATX-7-Q52HA </plain></SENT>
<SENT sid="10" pm="."><plain>Furthermore, shRNA-mediated suppression of ROCK1 or ROCK2 expression in 293 cells did not affect protein level of ATX-3-Q79HA or ATX-7-Q52HA and H1152 reduction of ATX-3-Q79HA </plain></SENT>
<SENT sid="11" pm="."><plain>Daily intraperitoneal administration of H1152 significantly decreased protein level of ATX-3-Q79HA in the cerebellum, pontine nuclei and spinal cord of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">SCA3</z:e> transgenic mice </plain></SENT>
<SENT sid="12" pm="."><plain>H1152 also ameliorated pontine neuronal <z:hpo ids='HP_0011420'>death</z:hpo> and neurological phenotype of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">SCA3</z:e> transgenic mice </plain></SENT>
<SENT sid="13" pm="."><plain>Our results suggest that H1152 might be an effective therapeutic agent for <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">SCA3</z:e> or <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">SCA7</z:e> </plain></SENT>
</text></document>